NASDAQ$NDSN

Nordson Corporation · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Nordson reported a decline in revenue and net income, with lower organic sales but strong backlog growth.

Nordson Corporation reported Q1 FY25 revenue of $615 million, a 2.8% decline year-over-year. Net income was $95 million, with EPS at $1.65 and adjusted EPS at $2.06. Despite lower organic sales, backlog grew 15% during the quarter, and order entry showed signs of improvement.

  • Revenue declined 2.8% year-over-year to $615 million.
  • Net income was $95 million, down from $110 million last year.
  • Adjusted EPS fell 7% to $2.06 per share.
  • Backlog increased by 15%, showing strong future demand.

Headline financials

Total Revenue

$615M

Previous: $633M-2.8%
EPS (adj)

$2.06

Previous: $1.90+8.4%
EBITDA

$188M

Previous: $197M-4.5%
EBITDA Margin

31.0%

No prior period
Gross Margin

54.6%

No prior period
Capital Expenditures

-$21.4M

Previous: -$7.53M-184.2%
Net Income

$94.7M

Previous: $110M-13.6%
Operating Income

$141M

Previous: $159M-11.6%
Gross Profit

$336M

Previous: $348M-3.6%

Revenue & EPS history

Nordson · Revenue · Quarterly

$615M

Q1 2025-2.8%vs Q1 2024
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Nordson · $741M total across 3 segments · Q2 2026

  • Industrial Precision Solutions
    $350M
  • Medical and Fluid Solutions
    $213M
  • Advanced Technology Solutions
    $178M

Forward guidance

Nordson expects Q2 FY25 revenue between $650M and $690M, with adjusted EPS projected between $2.30 and $2.50.

Tailwinds

  • Order entry momentum improved throughout the quarter.
  • Backlog growth of 15% positions the company for future revenue gains.
  • Strong operational execution despite weaker sales environment.
  • Diversified portfolio helps mitigate end-market volatility.
  • Confidence in long-term growth due to capital investment demand.

Headwinds

  • Macroeconomic conditions remain uncertain and volatile.
  • Organic sales trends continue to be weak in key segments.
  • Medical interventional solutions face ongoing customer destocking.
  • Foreign exchange rates negatively impacted revenue growth.
  • Acquisition-related amortization affects reported earnings.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+0.3%

Avg return

Earnings day

+0.2%

Avg return

5 days after

-0.5%

Avg return

30 days after

54%

37 / 69 earnings

Positive

+15.8%

Q4 2017

Best reaction

-14.8%

Q3 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026+1.8%
Q1 2026-1.7%-1.5%-12.2%
Q4 2025-0.3%+0.0%+10.5%
Q3 2025+2.9%+6.0%+5.4%
Q2 2025+6.8%+8.5%+9.9%
Q1 2025+0.3%-1.3%-6.4%
Q4 2024-9.4%-11.4%-20.9%
Q3 2024+6.9%+7.4%+6.7%
Q2 2024-10.5%-12.4%-14.5%
Q1 2024+3.5%+2.6%+1.7%
Q4 2023+5.1%+7.1%+5.8%
Q3 2023+1.5%+2.7%-2.0%
Q2 2023+1.1%+1.7%+8.8%
Q1 2023-13.9%-10.5%-15.6%
Q4 2022+1.5%-2.1%+2.3%
Q3 2022-2.1%-4.7%-10.4%
Q2 2022+2.7%+7.1%-3.8%
Q1 2022-3.5%-0.9%-1.1%
Q4 2021-5.9%-7.2%-9.9%
Q3 2021+2.2%+3.4%+4.0%
Q2 2021+7.4%+9.8%+8.0%
Q1 2021-0.0%+2.4%+6.3%
Q4 2020-2.9%-0.5%+1.2%
Q3 2020-7.1%-8.5%-6.6%
Q2 2020+1.7%+1.0%+12.4%
Q1 2020-0.3%-4.6%-37.9%
Q4 2019-1.6%-0.5%-1.2%
Q3 2019-3.0%-4.6%+5.9%
Q2 2019-1.0%-5.4%-1.6%
Q1 2019-3.0%-0.5%-8.1%
Q4 2018+7.7%+3.7%+10.9%
Q3 2018-0.9%+0.7%+7.1%
Q2 2018-4.2%-5.5%-3.3%
Q1 2018-2.0%-1.3%-3.9%
Q4 2017+15.8%+14.5%+19.5%
Q3 2017-10.2%-12.3%-5.3%
Q2 2017-5.9%-7.6%-8.2%
Q1 2017+0.1%+0.5%+2.0%
Q4 2016+5.2%+7.2%+7.0%
Q3 2016+10.6%+8.0%+7.1%
Q2 2016+15.7%+16.8%+12.2%
Q1 2016+9.1%
Q4 2015-8.1%
Q3 2015-14.8%
Q2 2015-1.4%
Q1 2015+0.0%
Q4 2014+2.3%
Q3 2014+0.8%
Q2 2014+9.2%
Q1 2014+2.0%
Q4 2013-2.3%
Q3 2013+0.1%
Q2 2013-7.4%
Q1 2013-9.8%
Q4 2012-1.4%
Q3 2012+10.6%
Q2 2012+10.5%
Q1 2012+5.0%
Q4 2011-1.9%
Q3 2011-3.0%
Q2 2011-1.1%
Q1 2010+1.5%
Q1 2011+3.3%
Q2 2010+2.1%
Q4 2010+2.1%
Q4 2008+2.1%
Q4 2009+0.2%
Q3 2009+0.2%
Q3 2010+0.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro